 Christian Young
Concepts (303)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 10 | 2024 | 642 | 1.930 |
Why?
| | Head and Neck Neoplasms | 9 | 2025 | 553 | 1.810 |
Why?
| | Mammary Neoplasms, Experimental | 5 | 2025 | 68 | 1.600 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 6 | 2025 | 97 | 1.440 |
Why?
| | Phosphatidylinositol 3-Kinases | 9 | 2022 | 368 | 1.150 |
Why?
| | Keratin-15 | 2 | 2025 | 17 | 1.110 |
Why?
| | Receptor, ErbB-2 | 10 | 2017 | 346 | 1.090 |
Why?
| | Receptor, ErbB-3 | 7 | 2017 | 46 | 1.080 |
Why?
| | Mouth Neoplasms | 3 | 2023 | 89 | 1.040 |
Why?
| | Breast Neoplasms | 12 | 2017 | 2250 | 1.010 |
Why?
| | Cell Line, Tumor | 21 | 2025 | 3469 | 0.830 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2023 | 72 | 0.760 |
Why?
| | Transforming Growth Factor beta | 7 | 2025 | 497 | 0.700 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2025 | 528 | 0.700 |
Why?
| | Mammary Glands, Animal | 5 | 2015 | 131 | 0.690 |
Why?
| | Precancerous Conditions | 1 | 2022 | 166 | 0.660 |
Why?
| | Proto-Oncogene Proteins c-akt | 9 | 2017 | 444 | 0.630 |
Why?
| | Smad7 Protein | 5 | 2025 | 19 | 0.620 |
Why?
| | Signal Transduction | 17 | 2025 | 5144 | 0.580 |
Why?
| | ErbB Receptors | 4 | 2022 | 610 | 0.550 |
Why?
| | Mammary Neoplasms, Animal | 3 | 2015 | 33 | 0.540 |
Why?
| | Mice, Nude | 11 | 2020 | 691 | 0.480 |
Why?
| | Mice | 28 | 2025 | 18048 | 0.460 |
Why?
| | Paracrine Communication | 1 | 2015 | 66 | 0.450 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 175 | 0.430 |
Why?
| | Protein Kinase Inhibitors | 3 | 2017 | 914 | 0.410 |
Why?
| | Animals | 36 | 2025 | 37657 | 0.400 |
Why?
| | Tumor Microenvironment | 6 | 2024 | 692 | 0.400 |
Why?
| | Phosphatidylinositol 3-Kinase | 2 | 2023 | 26 | 0.390 |
Why?
| | Disease Models, Animal | 9 | 2025 | 4404 | 0.370 |
Why?
| | Glucose Transporter Type 1 | 1 | 2011 | 48 | 0.350 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2025 | 137 | 0.350 |
Why?
| | B7-H1 Antigen | 2 | 2024 | 221 | 0.340 |
Why?
| | Stomatitis | 2 | 2021 | 14 | 0.330 |
Why?
| | Mucositis | 2 | 2021 | 20 | 0.320 |
Why?
| | Mice, Transgenic | 11 | 2025 | 2180 | 0.320 |
Why?
| | Cell Proliferation | 8 | 2020 | 2504 | 0.320 |
Why?
| | Smad4 Protein | 2 | 2020 | 35 | 0.310 |
Why?
| | Apoptosis | 4 | 2020 | 2574 | 0.300 |
Why?
| | Up-Regulation | 3 | 2024 | 859 | 0.290 |
Why?
| | Fats | 1 | 2008 | 18 | 0.280 |
Why?
| | Mutation | 3 | 2015 | 4013 | 0.280 |
Why?
| | Radiation Injuries, Experimental | 2 | 2025 | 22 | 0.270 |
Why?
| | Drug Resistance, Neoplasm | 7 | 2017 | 830 | 0.260 |
Why?
| | Neoplastic Stem Cells | 2 | 2022 | 400 | 0.260 |
Why?
| | Reactive Oxygen Species | 1 | 2009 | 630 | 0.250 |
Why?
| | Glucose | 2 | 2011 | 1041 | 0.250 |
Why?
| | rac1 GTP-Binding Protein | 2 | 2017 | 58 | 0.250 |
Why?
| | Keratinocytes | 3 | 2023 | 252 | 0.250 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2020 | 898 | 0.240 |
Why?
| | Wound Healing | 2 | 2018 | 348 | 0.240 |
Why?
| | Metaplasia | 1 | 2025 | 58 | 0.230 |
Why?
| | Genes, p53 | 2 | 2020 | 68 | 0.230 |
Why?
| | Radiodermatitis | 1 | 2025 | 10 | 0.230 |
Why?
| | Cell Plasticity | 1 | 2025 | 37 | 0.220 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 1787 | 0.220 |
Why?
| | Female | 28 | 2025 | 75515 | 0.220 |
Why?
| | Cachexia | 1 | 2025 | 72 | 0.220 |
Why?
| | Carcinogenesis | 2 | 2023 | 215 | 0.210 |
Why?
| | Phosphatidylinositols | 1 | 2023 | 59 | 0.200 |
Why?
| | Dermatitis | 1 | 2023 | 19 | 0.200 |
Why?
| | Receptors, Interleukin | 1 | 2023 | 45 | 0.200 |
Why?
| | Carcinogens | 1 | 2023 | 127 | 0.190 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2002 | 67 | 0.190 |
Why?
| | Glycerol | 1 | 2002 | 91 | 0.190 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 3 | 2017 | 62 | 0.190 |
Why?
| | Phosphorylation | 6 | 2015 | 1768 | 0.190 |
Why?
| | Antineoplastic Agents | 4 | 2017 | 2166 | 0.190 |
Why?
| | Immunologic Memory | 1 | 2024 | 360 | 0.190 |
Why?
| | Humans | 35 | 2024 | 141187 | 0.190 |
Why?
| | Laminin | 1 | 2022 | 72 | 0.190 |
Why?
| | Psoriasis | 1 | 2023 | 110 | 0.180 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2022 | 68 | 0.180 |
Why?
| | Biological Products | 1 | 2025 | 237 | 0.180 |
Why?
| | Neoplasms, Experimental | 2 | 2020 | 174 | 0.180 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2020 | 23 | 0.170 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2018 | 1431 | 0.170 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2017 | 53 | 0.160 |
Why?
| | Radiation Injuries | 1 | 2021 | 149 | 0.160 |
Why?
| | Hyaluronan Receptors | 1 | 2020 | 103 | 0.160 |
Why?
| | Tumor Burden | 3 | 2018 | 312 | 0.150 |
Why?
| | Cell Movement | 3 | 2018 | 990 | 0.150 |
Why?
| | Receptor, EphB3 | 1 | 2018 | 4 | 0.150 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 918 | 0.140 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 129 | 0.140 |
Why?
| | Estradiol | 2 | 2013 | 528 | 0.140 |
Why?
| | Estrogen Receptor Modulators | 2 | 2017 | 17 | 0.140 |
Why?
| | Protein Binding | 2 | 2015 | 2239 | 0.140 |
Why?
| | Multiprotein Complexes | 2 | 2016 | 169 | 0.140 |
Why?
| | Aminopyridines | 1 | 2018 | 104 | 0.140 |
Why?
| | Morpholines | 1 | 2018 | 126 | 0.140 |
Why?
| | Smokers | 1 | 2018 | 144 | 0.130 |
Why?
| | Lung Neoplasms | 3 | 2023 | 2560 | 0.130 |
Why?
| | Immunoblotting | 2 | 2011 | 310 | 0.130 |
Why?
| | Disease-Free Survival | 2 | 2015 | 715 | 0.130 |
Why?
| | Neoplasm Transplantation | 2 | 2014 | 250 | 0.120 |
Why?
| | Estrogen Receptor alpha | 1 | 2017 | 144 | 0.120 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2016 | 423 | 0.120 |
Why?
| | Quinazolines | 2 | 2017 | 250 | 0.120 |
Why?
| | Hyperplasia | 2 | 2013 | 176 | 0.120 |
Why?
| | Extracellular Matrix | 2 | 2022 | 555 | 0.120 |
Why?
| | Down-Regulation | 2 | 2015 | 641 | 0.120 |
Why?
| | Amphiregulin | 1 | 2015 | 25 | 0.120 |
Why?
| | Protein Kinase C-alpha | 1 | 2015 | 37 | 0.110 |
Why?
| | Neuropeptides | 1 | 2015 | 76 | 0.110 |
Why?
| | Antibodies, Neutralizing | 1 | 2017 | 305 | 0.110 |
Why?
| | Carrier Proteins | 2 | 2016 | 740 | 0.110 |
Why?
| | Cell Adhesion | 2 | 2022 | 468 | 0.110 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2015 | 139 | 0.110 |
Why?
| | Epidermal Growth Factor | 1 | 2015 | 176 | 0.110 |
Why?
| | Receptors, Estrogen | 1 | 2017 | 412 | 0.110 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 1123 | 0.110 |
Why?
| | Morphogenesis | 1 | 2015 | 171 | 0.110 |
Why?
| | Quinolines | 1 | 2015 | 160 | 0.110 |
Why?
| | Gene Expression | 3 | 2014 | 1491 | 0.110 |
Why?
| | Mice, Inbred C57BL | 5 | 2025 | 5887 | 0.110 |
Why?
| | Genes, erbB-2 | 1 | 2013 | 28 | 0.100 |
Why?
| | Transcriptome | 3 | 2018 | 1003 | 0.100 |
Why?
| | Skin | 3 | 2025 | 765 | 0.100 |
Why?
| | Immunotherapy | 1 | 2018 | 640 | 0.100 |
Why?
| | Receptors, Calcitriol | 2 | 2010 | 55 | 0.100 |
Why?
| | Autophagy | 1 | 2015 | 287 | 0.100 |
Why?
| | Chromatography, Liquid | 1 | 2015 | 453 | 0.100 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2012 | 333 | 0.100 |
Why?
| | Heterografts | 3 | 2018 | 134 | 0.100 |
Why?
| | Mammary Tumor Virus, Mouse | 2 | 2011 | 45 | 0.090 |
Why?
| | Rapamycin-Insensitive Companion of mTOR Protein | 3 | 2017 | 28 | 0.090 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2013 | 170 | 0.090 |
Why?
| | Dogs | 2 | 2025 | 427 | 0.090 |
Why?
| | Neoplasm Proteins | 1 | 2015 | 432 | 0.090 |
Why?
| | Immunohistochemistry | 2 | 2018 | 1737 | 0.090 |
Why?
| | Cell Line | 3 | 2015 | 2885 | 0.090 |
Why?
| | Tandem Mass Spectrometry | 1 | 2015 | 566 | 0.090 |
Why?
| | Gene Amplification | 3 | 2017 | 103 | 0.090 |
Why?
| | Pyrazoles | 1 | 2015 | 443 | 0.090 |
Why?
| | Inflammation | 2 | 2023 | 2890 | 0.090 |
Why?
| | Macrophages | 1 | 2019 | 1561 | 0.090 |
Why?
| | Skin Neoplasms | 1 | 2018 | 849 | 0.090 |
Why?
| | Mutation, Missense | 1 | 2013 | 339 | 0.090 |
Why?
| | Mice, Inbred BALB C | 3 | 2023 | 1274 | 0.090 |
Why?
| | Alkylating Agents | 1 | 2010 | 24 | 0.090 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2013 | 200 | 0.090 |
Why?
| | Transcription, Genetic | 1 | 2017 | 1487 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2019 | 2002 | 0.080 |
Why?
| | Calcitriol | 1 | 2010 | 59 | 0.080 |
Why?
| | Tumor Cells, Cultured | 3 | 2020 | 959 | 0.080 |
Why?
| | BRCA1 Protein | 1 | 2010 | 77 | 0.080 |
Why?
| | Neoplasm Staging | 3 | 2018 | 1398 | 0.080 |
Why?
| | Ovarian Neoplasms | 1 | 2015 | 580 | 0.080 |
Why?
| | Prognosis | 4 | 2020 | 4073 | 0.070 |
Why?
| | Cetuximab | 2 | 2020 | 105 | 0.070 |
Why?
| | Phthalazines | 2 | 2020 | 51 | 0.070 |
Why?
| | Proteomics | 1 | 2015 | 1134 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1056 | 0.070 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2008 | 126 | 0.070 |
Why?
| | Cell Death | 1 | 2009 | 386 | 0.070 |
Why?
| | Calcifediol | 1 | 2007 | 33 | 0.070 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2010 | 325 | 0.070 |
Why?
| | Vitamin D | 1 | 2010 | 397 | 0.070 |
Why?
| | Oxidative Phosphorylation | 1 | 2008 | 200 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinases | 2 | 2011 | 316 | 0.060 |
Why?
| | Enzyme Activation | 1 | 2008 | 811 | 0.060 |
Why?
| | Models, Biological | 2 | 2018 | 1828 | 0.060 |
Why?
| | Gene Expression Profiling | 1 | 2013 | 1764 | 0.060 |
Why?
| | Piperazines | 2 | 2020 | 354 | 0.060 |
Why?
| | Carcinoma | 1 | 2008 | 230 | 0.060 |
Why?
| | Male | 6 | 2025 | 69783 | 0.060 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 1448 | 0.060 |
Why?
| | MAP Kinase Signaling System | 2 | 2011 | 325 | 0.060 |
Why?
| | Kidney Neoplasms | 1 | 2010 | 405 | 0.060 |
Why?
| | Glycolysis | 1 | 2008 | 321 | 0.060 |
Why?
| | Cell Survival | 3 | 2015 | 1129 | 0.060 |
Why?
| | Molecular Targeted Therapy | 2 | 2020 | 419 | 0.060 |
Why?
| | Phenotype | 3 | 2023 | 3166 | 0.060 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2008 | 614 | 0.060 |
Why?
| | Blotting, Western | 3 | 2016 | 1234 | 0.060 |
Why?
| | SKP Cullin F-Box Protein Ligases | 1 | 2025 | 16 | 0.060 |
Why?
| | Tripartite Motif Proteins | 1 | 2025 | 41 | 0.060 |
Why?
| | Administration, Cutaneous | 1 | 2025 | 128 | 0.060 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 674 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2018 | 908 | 0.060 |
Why?
| | Muscular Atrophy | 1 | 2025 | 87 | 0.060 |
Why?
| | Lipid Metabolism | 1 | 2008 | 528 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 2 | 2018 | 386 | 0.050 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2025 | 175 | 0.050 |
Why?
| | MCF-7 Cells | 2 | 2014 | 126 | 0.050 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2025 | 216 | 0.050 |
Why?
| | Muscle Proteins | 1 | 2025 | 240 | 0.050 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2024 | 209 | 0.050 |
Why?
| | Phosphothreonine | 1 | 2002 | 6 | 0.050 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2023 | 174 | 0.050 |
Why?
| | Protein Phosphatase 2C | 1 | 2002 | 15 | 0.050 |
Why?
| | Nuclear Proteins | 1 | 2008 | 712 | 0.050 |
Why?
| | Osmosis | 1 | 2002 | 17 | 0.050 |
Why?
| | Glutathione Transferase | 1 | 2002 | 101 | 0.050 |
Why?
| | Protein Transport | 2 | 2017 | 448 | 0.050 |
Why?
| | Myeloid Cells | 1 | 2023 | 151 | 0.050 |
Why?
| | Cell Cycle Proteins | 2 | 2020 | 624 | 0.050 |
Why?
| | Catalytic Domain | 1 | 2002 | 224 | 0.050 |
Why?
| | Gene Products, tat | 1 | 2021 | 22 | 0.050 |
Why?
| | Luminescent Proteins | 1 | 2002 | 181 | 0.050 |
Why?
| | Biomarkers, Tumor | 2 | 2019 | 1251 | 0.040 |
Why?
| | Plasmids | 1 | 2002 | 365 | 0.040 |
Why?
| | Mitochondria | 1 | 2008 | 967 | 0.040 |
Why?
| | NF-kappa B | 1 | 2025 | 692 | 0.040 |
Why?
| | Microscopy, Fluorescence | 1 | 2002 | 417 | 0.040 |
Why?
| | Green Fluorescent Proteins | 1 | 2002 | 400 | 0.040 |
Why?
| | Epithelium | 2 | 2012 | 316 | 0.040 |
Why?
| | Disease Progression | 2 | 2020 | 2793 | 0.040 |
Why?
| | Zinc Finger E-box-Binding Homeobox 1 | 1 | 2020 | 24 | 0.040 |
Why?
| | Protein Structure, Tertiary | 1 | 2002 | 859 | 0.040 |
Why?
| | Feedback, Physiological | 1 | 2020 | 81 | 0.040 |
Why?
| | SOXB1 Transcription Factors | 1 | 2020 | 63 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2002 | 672 | 0.040 |
Why?
| | Transcription Factors | 1 | 2008 | 1703 | 0.040 |
Why?
| | Prostatic Neoplasms | 1 | 2007 | 1048 | 0.040 |
Why?
| | Temperature | 1 | 2002 | 669 | 0.040 |
Why?
| | Epithelial Cells | 2 | 2019 | 1110 | 0.040 |
Why?
| | Clodronic Acid | 1 | 2019 | 18 | 0.040 |
Why?
| | Kinetics | 1 | 2002 | 1652 | 0.040 |
Why?
| | Genes, Tumor Suppressor | 1 | 2019 | 82 | 0.040 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2002 | 403 | 0.040 |
Why?
| | RNA, Neoplasm | 1 | 2018 | 79 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2020 | 600 | 0.040 |
Why?
| | Guinea Pigs | 1 | 2018 | 171 | 0.040 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 208 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 37 | 0.040 |
Why?
| | Hyaluronic Acid | 1 | 2020 | 226 | 0.040 |
Why?
| | Nitric Oxide | 1 | 2023 | 900 | 0.040 |
Why?
| | Pregnancy | 1 | 2011 | 7070 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2002 | 2064 | 0.040 |
Why?
| | Fibrosis | 1 | 2020 | 541 | 0.040 |
Why?
| | Saccharomyces cerevisiae | 1 | 2002 | 556 | 0.040 |
Why?
| | Maytansine | 1 | 2017 | 18 | 0.030 |
Why?
| | rho Guanine Nucleotide Dissociation Inhibitor beta | 1 | 2017 | 4 | 0.030 |
Why?
| | Trastuzumab | 1 | 2017 | 96 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 429 | 0.030 |
Why?
| | Cyclin D1 | 1 | 2017 | 68 | 0.030 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2017 | 46 | 0.030 |
Why?
| | Monocytes | 1 | 2020 | 579 | 0.030 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2017 | 41 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2018 | 398 | 0.030 |
Why?
| | Cell Cycle | 2 | 2010 | 597 | 0.030 |
Why?
| | DNA Repair | 1 | 2019 | 234 | 0.030 |
Why?
| | Time Factors | 2 | 2010 | 6956 | 0.030 |
Why?
| | RNA Interference | 1 | 2018 | 469 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2016 | 52 | 0.030 |
Why?
| | Fibroblast Growth Factors | 1 | 2017 | 180 | 0.030 |
Why?
| | Bone Morphogenetic Protein Receptors | 1 | 2015 | 6 | 0.030 |
Why?
| | DNA Damage | 1 | 2018 | 427 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 2017 | 1093 | 0.030 |
Why?
| | Ligands | 1 | 2017 | 667 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1243 | 0.030 |
Why?
| | Muscle, Skeletal | 1 | 2025 | 1752 | 0.030 |
Why?
| | Organ Culture Techniques | 1 | 2015 | 157 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2015 | 129 | 0.030 |
Why?
| | Spheroids, Cellular | 1 | 2015 | 77 | 0.030 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2014 | 41 | 0.030 |
Why?
| | Biomarkers | 2 | 2018 | 4174 | 0.030 |
Why?
| | Genes, myc | 1 | 2013 | 48 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2014 | 245 | 0.030 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2013 | 40 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2015 | 509 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2013 | 111 | 0.030 |
Why?
| | Cisplatin | 1 | 2015 | 327 | 0.030 |
Why?
| | Neoplasm, Residual | 1 | 2013 | 132 | 0.020 |
Why?
| | Gene Dosage | 1 | 2013 | 141 | 0.020 |
Why?
| | DNA Copy Number Variations | 1 | 2013 | 176 | 0.020 |
Why?
| | Drug Synergism | 1 | 2013 | 375 | 0.020 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2014 | 231 | 0.020 |
Why?
| | Phagocytosis | 1 | 2014 | 388 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2013 | 521 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2017 | 852 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 2011 | 145 | 0.020 |
Why?
| | Postpartum Period | 1 | 2014 | 353 | 0.020 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2013 | 213 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2013 | 761 | 0.020 |
Why?
| | Cell Growth Processes | 1 | 2011 | 53 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2018 | 11120 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2014 | 623 | 0.020 |
Why?
| | Cyclin A | 1 | 2010 | 18 | 0.020 |
Why?
| | Alkylation | 1 | 2010 | 27 | 0.020 |
Why?
| | Neoadjuvant Therapy | 1 | 2013 | 419 | 0.020 |
Why?
| | Oligonucleotides, Antisense | 1 | 2011 | 112 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2010 | 209 | 0.020 |
Why?
| | Survival Analysis | 1 | 2013 | 1319 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 2999 | 0.020 |
Why?
| | Receptor, IGF Type 1 | 1 | 2010 | 64 | 0.020 |
Why?
| | Caspases | 1 | 2010 | 245 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2010 | 154 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2010 | 183 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2010 | 161 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 987 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2011 | 792 | 0.020 |
Why?
| | Estrogens | 1 | 2010 | 367 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2010 | 1357 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2010 | 739 | 0.020 |
Why?
| | Cytokines | 1 | 2014 | 2098 | 0.020 |
Why?
| | Biological Transport | 1 | 2007 | 407 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 2012 | 892 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2010 | 4208 | 0.010 |
Why?
| | Aged | 1 | 2018 | 24574 | 0.010 |
Why?
| | Middle Aged | 1 | 2018 | 34434 | 0.010 |
Why?
|
|
Young's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|